{"entity": "publication", "iuid": "cb83afb7a90f466daef8d0d7c489c25f", "timestamp": "2026-09-08T10:05:16.900Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/cb83afb7a90f466daef8d0d7c489c25f.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/cb83afb7a90f466daef8d0d7c489c25f"}}, "title": "Endogenous incretin levels and risk of first incident cancer: a prospective cohort study.", "authors": [{"family": "Juji\u0107", "given": "Amra", "initials": "A"}, {"family": "Godina", "given": "Christopher", "initials": "C"}, {"family": "Belting", "given": "Mattias", "initials": "M"}, {"family": "Melander", "given": "Olle", "initials": "O"}, {"family": "Juul Holst", "given": "Jens", "initials": "J"}, {"family": "Ahlqvist", "given": "Emma", "initials": "E"}, {"family": "Gomez", "given": "Maria F", "initials": "MF"}, {"family": "Nilsson", "given": "Peter M", "initials": "PM"}, {"family": "Jernstr\u00f6m", "given": "Helena", "initials": "H"}, {"family": "Magnusson", "given": "Martin", "initials": "M"}], "type": "journal article", "published": "2023-01-07", "journal": {"title": "Sci Rep", "issn": "2045-2322", "volume": "13", "issue": "1", "pages": "382", "issn-l": "2045-2322"}, "abstract": "Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malm\u00f6 Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 \u00b1 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82-0.99; p = 0.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer.", "doi": "10.1038/s41598-023-27509-3", "pmid": "36611045", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9825393"}, {"db": "pii", "key": "10.1038/s41598-023-27509-3"}], "notes": [], "created": "2026-08-21T11:53:54.190Z", "modified": "2026-08-21T11:53:54.203Z"}